Raynauds Disease - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 67 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Raynauds Disease - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Raynauds Disease - Pipeline Review, H2 2014', provides an overview of the Raynauds Disease's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Raynauds Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Raynauds Disease and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Raynauds Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Raynauds Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Raynauds Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Raynauds Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Raynauds Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Raynauds Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Raynauds Disease Overview 6
Therapeutics Development 7
Pipeline Products for Raynauds Disease - Overview 7
Pipeline Products for Raynauds Disease - Comparative Analysis 8
Raynauds Disease - Therapeutics under Development by Companies 9
Raynauds Disease - Therapeutics under Investigation by Universities/Institutes 10
Raynauds Disease - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Raynauds Disease - Products under Development by Companies 14
Raynauds Disease - Products under Investigation by Universities/Institutes 15
Raynauds Disease - Companies Involved in Therapeutics Development 16
Allergan, Inc. 16
Apricus Biosciences, Inc. 17
Bayer AG 18
Mezzion Pharma Co. Ltd. 19
Nippon Shinyaku Co., Ltd. 20
Teva Pharmaceutical Industries Limited 21
Raynauds Disease - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
alprostadil - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ELS-140 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
MDT-012 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
onabotulinumtoxin A - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
riociguat - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
selexipag - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules to Inhibit Alpha 2 Adrenergic Receptor for Raynauds Disease - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
udenafil - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Raynauds Disease - Recent Pipeline Updates 45
Raynauds Disease - Dormant Projects 59
Raynauds Disease - Discontinued Products 60
Raynauds Disease - Product Development Milestones 61
Featured News & Press Releases 61
Dec 04, 2014: Apricus Biosciences Announces First Patient Enrolled In Phase 2a Clinical Trial For RayVa In Patients With Raynaud's Phenomenon 61
Oct 13, 2014: Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application for RayVa 62
Oct 01, 2014: Apricus Biosciences to Present at the 13th Annual BIO Investor Forum 62
May 12, 2014: Apricus Biosciences Receives FDA Clearance to Begin Clinical Trial of RayVa for Secondary Raynaud's Phenomenon 63
May 31, 2011: Apricus Bio Receives Israeli Patent For RayVa For Raynaud's Phenomenon 63
Apr 13, 2011: Apricus Bio Files For Orphan Drug Designation For RayVa 64
Sep 22, 2010: FDA Guides Apricus Bio On RayVa's Approvability For Raynaud's Syndrome Secondary To Scleroderma 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 67
Disclaimer 67

List of Tables
Number of Products under Development for Raynauds Disease, H2 2014 7
Number of Products under Development for Raynauds Disease - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Raynauds Disease - Pipeline by Allergan, Inc., H2 2014 16
Raynauds Disease - Pipeline by Apricus Biosciences, Inc., H2 2014 17
Raynauds Disease - Pipeline by Bayer AG, H2 2014 18
Raynauds Disease - Pipeline by Mezzion Pharma Co. Ltd., H2 2014 19
Raynauds Disease - Pipeline by Nippon Shinyaku Co., Ltd., H2 2014 20
Raynauds Disease - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 21
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 26
Number of Products by Stage and Route of Administration, H2 2014 28
Number of Products by Stage and Molecule Type, H2 2014 30
Raynauds Disease Therapeutics - Recent Pipeline Updates, H2 2014 45
Raynauds Disease - Dormant Projects, H2 2014 59
Raynauds Disease - Discontinued Products, H2 2014 60